Background: Prescription opioid (RxO) abuse, dependence and misuse is a significant and growing problem in the US, and is associated with a substantial economic burden. Such abuse may be reduced by theoretical formulations that minimize the possibility of abuse, dependence and misuse of RxOs by injection, snorting, crushing or chewing. As well as public health and safety benefits, use of an abuse-deterrent/resistant RxO (ADO) that may deter abuse, dependence and misuse could also generate cost savings.
Objectives: To estimate potential annual cost savings to US third-party payers realized from introducing a theoretical ADO.
Methods: A budget-impact model (BIM) was developed to assess potential cost savings from the introduction of an ADO to third-party payers. The BIM included information on ADO attributes, costs associated with RxO abuse-related episodes, prevalence of RxO abuse and potential market share capture of the new ADO. Numbers of abuse-related episodes were calculated using a database on admissions to substance abuse treatment centres and other national surveys. Direct (medical and pharmaceutical) costs associated with RxO abuse, dependence and misuse were calculated using de-identified employer claims data (n > 6 000 000) for costs of abuse-related episodes. All cost estimates are in $US, year 2006 values. The BIM was developed for a theoretical prescription drug with therapeutic properties similar to those of controlled-release oxycodone, in a formulation that is specifically designed to resist or deter common methods of abuse, including injection, crushing, snorting and chewing.
Results: Potential cost savings to third-party payers from introducing an ADO for the US (assuming a privately insured cost structure) could range from approximately $US0.6 billion to $US1.6 billion per year depending on different possible scenarios.
Conclusion: While savings estimates from introduction of an ADO depend on a range of assumptions, cost savings would be substantial.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF03256142 | DOI Listing |
BMJ Open
January 2025
Department of Medical Oncology, Section Translational Medical Ethics, National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
Objectives: Patient-reported financial effects of a tumour disease in a universal healthcare setting are a multidimensional phenomenon. Actual and anticipated objective financial burden caused by direct medical and non-medical costs as well as indirect costs such as loss of income can lead to subjective financial distress. To better understand subjective financial distress, the presented study explores self-reported determinants for subjective financial distress in German patients with cancer, aiming to inform a new German-language patient-reported outcome measure for determining the financial effects of a tumour disease.
View Article and Find Full Text PDFValue Health
January 2025
Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Objectives: We investigated how the Inflation Reduction Act (IRA) Medicare Part D benefit redesign may reduce out-of-pocket (OOP) drug expenditures for Medicare beneficiaries with dementia. Methods Design Utilizing data from the Health and Retirement Study (HRS) linked with Medicare claims, we simulated post-redesign OOP drug spending by applying the 2025 prescription drug cost-sharing rules to each beneficiary's pre-redesign Part D medication utilization data for 2016, adjusting for inflation. Participants Our study population comprised HRS respondents aged 65 and older in 2016, enrolled in Medicare fee-for-service, with at least one Part D drug claim in 2016, and diagnosed with dementia between 2000 and 2016 (n=1,677).
View Article and Find Full Text PDFJ Arthroplasty
January 2025
The Rubin Institute for Advanced Orthopedics, Baltimore, Maryland. Electronic address:
Introduction: Smartphone and wearable technologies are novel devices for monitoring postoperative mobility and recovery in total knee arthroplasty (TKA) patients. This systematic review of the highest-level evidence studies evaluated the advantages of these technologies in postoperative care, specifically focusing on 1) smartphone applications, 2) wearable devices, and 3) their combined use.
Methods: A systematic literature search from July 26, 2015, to June 13, 2024, identified Level-1 and -2 published studies investigating smartphone applications and wearables for monitoring post-TKA recovery.
Neural Netw
January 2025
School of Computer Science, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom.
Learning from data streams that emerge from nonstationary environments has many real-world applications and poses various challenges. A key characteristic of such a task is the varying nature of the underlying data distributions over time (concept drifts). However, the most common type of data stream learning approach are ensemble approaches, which involve the training of multiple base learners.
View Article and Find Full Text PDFJ Comp Eff Res
January 2025
Abbott Rapid Diagnostics, 110 Viale Thomas Alva Edison, Sesto San Giovanni, MI, Italy, 2009.
Screening and monitoring of diabetes or dyslipidemia frequently involves a multi-step process requiring patients to obtain test requisitions from their primary care physician (PCP), followed by a laboratory visit and re-consultation. Point-of-care testing (POCT) for hemoglobin A (HbA) and lipid panel can streamline the patient care pathway. This study assessed the budget impact of introducing Afinion™ 2 POCT (Abbott Rapid Diagnostics) from the Canadian and Italian societal perspectives.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!